About US
Contact us
-
Gilead's Vemlidy enters the pediatric hepatitis B arena with FDA green lightAmid Gilead Science’s oncology push, the company hasn’t forgotten about its hepatitis portfolio. The latest evidence? Gilead's chronic hepatitis B virus (HBV) drug Vemlidy scored a new indication to2022/11/2
-
GSK's Shingrix rebound rolls on with record sales, but looming Zantac lawsuits raise M&A doubtsIn GSK’s first quarter after the Haleon consumer health spinoff, shingles vaccine Shingrix put up another record show. But while a cloud of Zantac lawsuits gathers over the company, CEO Emma Walmsley2022/10/31
-
Alkermes joins Bristol Myers in IL-2 exit with oncology business spinoffInstead of the garden-variety symphony music favored by most pharma companies before entering a conference call, Alkermes selected Fleetwood Mac’s breakup anthem “Go Your Own Way.”2022/10/31
-
GSK's oral anemia drug bruised with FDA panel partial snub in chronic kidney diseaseFollowing two FDA rejections of novel oral anemia drugs, all eyes are on GSK’s daprodustat. Now, the drug has come out of an FDA panel meeting partially bruised, losing experts' support in one of the2022/10/27
-
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO saysEven as Revlimid generics chip away at Bristol Myers Squibb's top line, the companyremains confident it can shepherd its roster of new drugs toward more than $25 billion in revenues by 2029, executiv2022/10/27
-
J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapyAfter European regulators jumped on a global-first approval for Johnson & Johnson’s BCMA-targeted bispecific drug Tecvayli, the U.S. FDA has doled out its own blessing for the novel therapy. But2022/10/24
-
GSK shuffles execs and streamlines businesses as vaccines chief Connor heads for the exitNow unburdened by its consumer health division, GSK is streamlining its drug and vaccines businesses and shuffling executives in turn. On the quest to simplify its operations in a post-Ha2022/10/24
-
FDA approves single-vial version of GSK's Menveo vaccine, ending need for reconstitutionGSK haswonFDA approval for a single-vial formulation of its meningococcal disease vaccine Menveo, thereby ending the need for reconstitution that has existed since the product came to market in 2010.2022/10/19
-
Roche recalls new eye therapy Susvimo on leakage fears, aims for market return 'within a year or so'Just as doctors were starting to cozy up to Roche and Genentech’s new eye drug delivery therapy, the companies are pulling the product from U.S. shelves. Roche has launched a voluntary re2022/10/19
-
Love Pharma moves to buy transdermal opioid-use disorder playerLove Pharma hasstrucka deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a treat2022/10/17